GOSS NASDAQ
Gossamer Bio, Inc.
1W: +0.7%
1M: -16.2%
3M: -41.7%
YTD: -95.8%
1Y: -95.1%
3Y: -77.7%
5Y: -99.1%
$9.77
+0.62 (+6.78%)
Weekly Expected Move ±11.4%
$7
$9
$10
$11
$12
Credit Risk of going bust: higher than 94% of companies Debt: 39.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.91 (down 80%), Gossamer Bio, Inc. would be worth roughly what it owes.
Total debt $39.1M against a stock market value of $59.7M.
Distance to default 0.81 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $36.1M (short-term plus half of long-term), stock volatility 117.3%; Altman Z'' -86.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $1.91 (down 80%), Gossamer Bio, Inc. would be worth roughly what it owes.
Total debt $39.1M against a stock market value of $59.7M.
Distance to default 0.81 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $36.1M (short-term plus half of long-term), stock volatility 117.3%; Altman Z'' -86.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
2 relationships2
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2024-05-06
Earliest Filing
2024-05-06
Latest Filing
partner: 2
Counterparties (Filed by GOSS)
2 relationshipsCompanies named in GOSS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Chiesi Farmaceutici S.p.A | — | partner | Entered into a global collaboration and license agreement for the development and commercialization of seralutinib. | 2024-05-06 | View |
| Chiesi USA, Inc. | — | partner | Joint partner with Chiesi Farmaceutici S.p.A in the global collaboration and license agreement. | 2024-05-06 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-28 | Other Events | View | |
| 2026-09-23 | Other Events | View | |
| 2026-09-16 | Officer/Director Change; Exhibits | View | |
| 2026-09-11 | Bylaws Amendment; Other Events; Exhibits | View | |
| 2026-09-09 | Other Events; Exhibits | View | |
| 2026-09-03 | Bylaws Amendment; Exhibits | View | |
| 2026-08-26 | Bylaws Amendment; Exhibits | View | |
| 2026-08-21 | Material Agreement; Unregistered Equity Sales; Bylaws Amendment; Regulation FD; Exhibits | Agreement | View |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-07-27 | Material Agreement; Termination of Agreement; Earnings Release; Regulation FD; Other Events; Exhibit | Agreement | View |
| 2026-07-15 | Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-07-01 | Regulation FD; Exhibits | View | |
| 2026-06-17 | Regulation FD; Exhibits | View | |
| 2026-06-05 | Material Agreement; Termination of Agreement; Financial Obligation; Unregistered Equity Sales; Regul | Agreement | View |
| 2026-06-05 | Shareholder Vote | View | |
| 2026-06-02 | Other Events; Exhibits | View | |
| 2026-05-18 | Material Agreement; Earnings Release; Officer/Director Change; Regulation FD; Other Events | Agreement | View |
| 2026-04-09 | Delisting Notice | View | |
| 2026-03-17 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-23 | Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR